← All work

The story / 2014 / Merck / at Continuum Clinical

Keynote

The identity for the trial program behind the world’s best-selling medicine.

Logo and website, designed by me / Patient materials, designed or directed

The Keynote website home page on a desktop monitor

In 2014, immunotherapy was still new, and Merck had one investigational drug about to be studied across multiple cancers. We were brought in to give the research one identity that could grow with the program.

The mark

A power already inside.

The idea started with a question: what if you had a cancer-fighting superpower? The “o” in Keynote became a ring of color, the patient’s own power to fight back. As the program grew, each arc took the color of a cancer under study, so one mark could hold the whole program.

A woman at the center of the Keynote rings

The idea

The person at the center.

Immunotherapy helps the body’s own immune system fight cancer. So the rings don’t sit beside people. They surround them. In every image, the patient is at the center of the circle.

The system

From screen to waiting room.

The same ring carried from the website into study site posters and physician flyers, always pointing patients toward a conversation with their physician.

Keynote poster for participating clinical study sites
In the waiting room / Study site poster
Keynote lung cancer clinical trials flyer for physicians
For physicians / Study flyer

What happened next

The ring outgrew the name.

As the program grew, the ring became the visual system for Merck Oncology Clinical Trials. Each cancer took its own color, each study its own numbered mark, and every patient stayed at the center of the circle.

My role / Designed or directed the system as it scaled

The architecture

One ring, three levels.

Compound

Keytruda (pembrolizumab)

Indication

Clinical trials forBreast
Clinical trials forHead and neck
Clinical trials forHematology

Study

Keynote 522 trial mark, locally advanced triple negative breast cancer
Keynote 412 trial mark, locally advanced head and neck squamous cell carcinoma
Keynote 185 trial mark, multiple myeloma

Breast

Keynote 522 trial mark, locally advanced triple negative breast cancer

Head and neck

Keynote 412 trial mark, locally advanced head and neck squamous cell carcinoma

Hematology

Keynote 185 trial mark, multiple myeloma

Choose a color

Lung: Trial ad Non-small cell lung cancerMelanoma: Trial ad High-risk stage II melanomaBreast: Study adLiver: Trial adHead and neck: Study flyer Head and neck squamous cell carcinomaHematology: Trial mark Keynote 185, multiple myelomaBladder: Social adEndometrial: Social adKidney: Study flyer Renal cell carcinoma

The scale

3 levelscompound, indication and study, one ring
1,600+Keytruda studies by 2023
16cancer types with approved uses by 2023

Keynote was the trial program behind Keytruda, which became the world’s best-selling medicine. For years after, it was the bar every new piece of work was measured against. When the Keynote name was retired, the ring carried on as the identity for Merck Oncology Clinical Trials.

ClientMerck & Co., Inc.

AgencyContinuum Clinical

My roleLogo and website design; patient materials and the later system designed or directed

More work Let’s talk LinkedIn